DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactIPO

Molbio Diagnostics IPO listing date today. Here's what GMP, experts signal ahead of debut

livemint.com 18 hrs ago·16 Aug 2026, 10:30 am

MOLBIO livemint.com

Molbio Diagnostics is set to list on the stock market today, marking the conclusion of its initial public offering (IPO). The company, which specializes in molecular diagnostics, raised funds through this offering to support its expansion plans and strengthen its financial position. Investors have been closely watching the grey market premium (GMP), which reflects the market's expectations for the listing price, as it often provides an early indication of the stock's performance post-debut.

The listing of Molbio is significant as it offers retail investors an opportunity to participate in the growth story of a company operating in the healthcare and diagnostics sector. The company's expertise in testing solutions positions it well in a market that has seen increased demand for diagnostic services. Market experts have been divided in their views, with some expressing optimism about the stock's potential while others remain cautious about the competitive landscape and valuation.

Investors should monitor the listing price, the volume of trading, and the overall market sentiment following the debut. The stock's performance in the initial days will be crucial in determining its short-term trajectory. It is advisable for investors to conduct their own research and consider their risk appetite before making any investment decisions.